Disease · MONDO_0002926
clear cell sarcoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. clear cell sarcoma. Diseases, record MONDO_0002926. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002926
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
adult soft part clear cell sarcoma, chordoid sarcoma, clear cell sarcoma (morphologic abnormality), clear cell sarcoma - not kidney, clear cell sarcoma of soft parts, clear cell sarcoma of soft tissue, clear cell sarcoma/malignant melanoma of soft parts (excluding clear cell sarcoma of the kidney), malignant melanoma of soft tissues, malignant melanoma of the soft parts, melanoma, malignant, of soft parts
- Open Targets
- Highest stage of its drugs
- Phase 2, for 11 of its 21 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs21
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AMG-337 | CHEMBL3785909 | Small molecule | Phase 2 | ClinicalTrials.gov and TTD | 2 | 1 | 1 | Drugs and targets |
| ATEZOLIZUMAB | CHEMBL3707227 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CRIZOTINIB | CHEMBL601719 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOSTARLIMAB | CHEMBL4298124 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIVOCERANIB | CHEMBL3186534 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TEBENTAFUSP | CHEMBL4297990 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TEPROTUMUMAB | CHEMBL1743079 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TIVANTINIB | CHEMBL2103882 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VEBRELTINIB | CHEMBL4650443 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 21
See all 21 drugsTargets25
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| MET | Hepatocyte growth factor receptor | 3 | Hepatocyte growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/4233 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 2 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| ALK | ALK tyrosine kinase receptor | 1 | ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor | Phase 2 | https://conductscience.org/library/genes/238 | Drugs and targets |
| BRAF | Serine/threonine-protein kinase B-raf | 1 | Serine/threonine-protein kinase B-raf inhibitor | Phase 2 | https://conductscience.org/library/genes/673 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 1 | Programmed cell death 1 ligand 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| CSF1R | Macrophage colony-stimulating factor 1 receptor | 1 | Macrophage colony stimulating factor receptor inhibitor | Phase 1/2 | https://conductscience.org/library/genes/1436 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Phase 1/2 | https://conductscience.org/library/genes/1719 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 1 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| EML4 | EML4-ALK | 1 | EML4-ALK inhibitor | Phase 2 | https://conductscience.org/library/genes/27436 | Drugs and targets |
1 to 10 of 25
See all 25 targetsTrials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00642941 | A Study of R1507 in Participants With Recurrent or Refractory Sarcoma | Phase 2 | 317 | 2021-02-03 | Sarcoma | TEPROTUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01524978 | A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers | Phase 2 | 208 | 2017-11-20 | Multiple Myeloma, Neoplasms | CETUXIMAB, VEMURAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT04458922 | Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma | Phase 2 | 27 | 2023-10-23 | Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma | ATEZOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03132155 | QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma | Phase 2 | 8 | 2024-05-24 | Clear Cell Sarcoma | AMG-337 | Its record names the disease | ClinicalTrials.gov |
| NCT01524926 | CREATE: Cross-tumoral Phase 2 With Crizotinib | Phase 2 | 582 | Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma, Locally Advanced and/or Metastatic Clear Cell Sarcoma, Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma | CRIZOTINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03277924 | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas | Phase 1/2 | 197 | Soft Tissue Sarcoma, Bone Sarcoma | CISPLATIN, DACARBAZINE, DOXORUBICIN, EPIRUBICIN, IFOSFAMIDE, METHOTREXATE, NIVOLUMAB, SUNITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03064243 | A Phase II Study of Apatinib in STS Patients | Phase 2 | 53 | Soft Tissue Sarcoma | RIVOCERANIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00557609 | Phase 2 Study in Patients With MiT Tumors | Phase 2 | 47 | Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS), Clear Cell Sarcoma (CCS) | TIVANTINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT06942442 | A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma | Phase 2 | 47 | HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS) | TEBENTAFUSP | Its record names the disease | ClinicalTrials.gov | |
| NCT07153887 | Vebreltinib for Advanced or Metastatic CCS | Phase 2 | 30 | Clear Cell Sarcoma (CCS) | VEBRELTINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab vs Pooled Arm - Vemurafenib: serious adverse events | 11 of 27 | 91 of 181 | 208 | NCT01524978 |
Source Trial comparisons
Papers from its trials17
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 42376809 | DERIVED | 1 | PubMed |
| 41836677 | DERIVED | 1 | PubMed |
| 39356980 | DERIVED | 1 | PubMed |
| 37934000 | DERIVED | 1 | PubMed |
| 36267741 | DERIVED | 1 | PubMed |
| 34392187 | DERIVED | 1 | PubMed |
| 33203665 | DERIVED | 1 | PubMed |
| 31401903 | DERIVED | 1 | PubMed |
| 30351999 | DERIVED | 1 | PubMed |
| 29669701 | DERIVED | 1 | PubMed |
1 to 10 of 17
See all 17 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002926
GET https://conductscience.org/api/diseases/v1/MONDO_0002926/drugs?page=2